157 related articles for article (PubMed ID: 33941865)
41. Association of race/ethnicity and patient care experiences with receipt of definitive treatment among prostate cancer survivors: a SEER-CAHPS study.
Pandit AA; Halpern MT; Gressler LE; Kamel M; Payakachat N; Li C
Cancer Causes Control; 2024 Apr; 35(4):647-659. PubMed ID: 38001335
[TBL] [Abstract][Full Text] [Related]
42. The Relative Importance of Race Compared to Health Care and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach.
Hanson HA; Martin C; O'Neil B; Leiser CL; Mayer EN; Smith KR; Lowrance WT
J Urol; 2019 Dec; 202(6):1209-1216. PubMed ID: 31246547
[TBL] [Abstract][Full Text] [Related]
43. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
44. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
Lee WR; Hanks GE; Hanlon A
J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
[TBL] [Abstract][Full Text] [Related]
45. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
46. Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors.
Taussky D; Piotte J; Zorn KC; Zanaty M; Krishnan V; Lambert C; Bahary JP; Beauchemin MC; Barkati M; Ménard C; Delouya G
Strahlenther Onkol; 2018 Jan; 194(1):17-22. PubMed ID: 28695317
[TBL] [Abstract][Full Text] [Related]
47. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
Bryant AK; D'Amico AV; Nguyen PL; Einck JP; Kane CJ; McKay RR; Simpson DR; Mundt AJ; Murphy JD; Rose BS
Cancer; 2018 Jul; 124(14):2939-2947. PubMed ID: 29727915
[TBL] [Abstract][Full Text] [Related]
48. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
49. Receipt of National Comprehensive Cancer Network guideline-concordant prostate cancer care among African American and Caucasian American men in North Carolina.
Ellis SD; Blackard B; Carpenter WR; Mishel M; Chen RC; Godley PA; Mohler JL; Bensen JT
Cancer; 2013 Jun; 119(12):2282-90. PubMed ID: 23575751
[TBL] [Abstract][Full Text] [Related]
50. Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study.
Hoffman RM; Mott SL; McDowell BD; Anand ST; Nepple KG
Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):100-108. PubMed ID: 34108645
[TBL] [Abstract][Full Text] [Related]
51. Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter?
Moses KA; Orom H; Brasel A; Gaddy J; Underwood W
Urology; 2017 Jan; 99():76-83. PubMed ID: 27667157
[TBL] [Abstract][Full Text] [Related]
52. Prostate-specific antigen testing among young men: an opportunity to improve value.
Lange SM; Ambrose JP; Flynn MC; Lowrance WT; Hanson HA; O'Neil BB
Cancer Med; 2021 Mar; 10(6):2075-2079. PubMed ID: 33626214
[TBL] [Abstract][Full Text] [Related]
53. Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
Cao Y; Zhang W; Li Y; Fu J; Li H; Li X; Gao X; Zhang K; Liu S
Prostate; 2021 Oct; 81(14):1071-1077. PubMed ID: 34320230
[TBL] [Abstract][Full Text] [Related]
54. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends.
Tang C; Hoffman KE; Allen PK; Gabel M; Schreiber D; Choi S; Chapin BF; Nguyen QN; Davis JW; Corn P; Logothetis C; Ward J; Frank SJ; Navai N; McGuire SE; Anscher M; Pisters L; Pettaway CA; Kumar R; Linson P; Tripuraneni P; Tomaszewski JJ; Patel AB; Augspurger M; Kuban DA
Cancer; 2020 Feb; 126(3):506-514. PubMed ID: 31742674
[TBL] [Abstract][Full Text] [Related]
55. Circulating Prostate-Specific Antigen and Telomere Length in a Nationally Representative Sample of Men Without History of Prostate Cancer.
Wulaningsih W; Astuti Y; Matsuguchi T; Anggrandariyanny P; Watkins J;
Prostate; 2017 Jan; 77(1):22-32. PubMed ID: 27566127
[TBL] [Abstract][Full Text] [Related]
56. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.
Vickers AJ; Sjoberg DD; Ulmert D; Vertosick E; Roobol MJ; Thompson I; Heijnsdijk EA; De Koning H; Atoria-Swartz C; Scardino PT; Lilja H
BMC Med; 2014 Feb; 12():26. PubMed ID: 24512643
[TBL] [Abstract][Full Text] [Related]
57. Outcomes of localized prostate cancer following conservative management.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Barry MJ; Zietman A; O'Leary M; Walker-Corkery E; Yao SL
JAMA; 2009 Sep; 302(11):1202-9. PubMed ID: 19755699
[TBL] [Abstract][Full Text] [Related]
58. PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.
Magnani CJ; Li K; Seto T; McDonald KM; Blayney DW; Brooks JD; Hernandez-Boussard T
J Natl Compr Canc Netw; 2019 Jul; 17(7):795-803. PubMed ID: 31319390
[TBL] [Abstract][Full Text] [Related]
59. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
60. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
